查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790499

Erleada 市场规模、份额和趋势分析报告：按类型、分销管道、地区和细分市场预测，2025 年至 2033 年

Erleada Market Size, Share & Trends Analysis Report By Type (Branded, Generic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

阿莱达市场摘要

2024 年全球 ERDA 市场价值估计为 29.99 亿美元，预计到 2033 年将达到 61.66 亿美元，2025 年至 2033 年的复合年增长率为 7.99%。 ERDA 产业越来越注重联合治疗，以改善转移性去势抗性前列腺癌 (mCRPC) 的治疗效果。

计划于 2027 年完成的 III 期临床试验（例如 NCT02257736）正在评估阿帕鲁胺与醋酸Abiraterone和泼尼鬆的联合用药效果，以建立协同作用并探索潜在的适应症扩展。利用临床数据，例如 SPARTAN 试验中转移风险降低 70%（HR 0.28），相关人员可以加强与付款人的谈判并保持市场吸引力。重视联合治疗加强了 Erleada 对抗新兴学名药的地位，例如 Zydus Lifesciences 的阿帕鲁胺片，该片于 2025 年 3 月获得美国 FDA核准，威胁到 Erleada 的市场独占权。强生公司的专利涵盖某些製剂直至 2038 年，为患者提供法律保护，但诉讼的可能性仍然令人担忧。

市场受到价值导向医疗日益普及的影响，尤其是像联邦医疗保险（Medicare）这样的美国支付机构，他们更青睐那些经证实具有长期效益的治疗方法。阿帕鲁胺的临床证据，包括使用TITAN后死亡风险降低33%（HR 0.67），正在产生现实影响，因为联邦医疗保险优势计划报告称，到2024年，与替代疗法相比，非去势抵抗性前列腺癌（nmCRPC）患者的住院率降低了10%。透过产生现实证据来证明成本效益，并投资于医疗服务提供者关于阿帕鲁胺给药的教育，相关人员可以增强市场韧性，促进其应用，并减轻学名药竞争的影响。

ERLEAD® 产业受益于人们对早期前列腺癌筛检认识的提升，并受益于美国预防服务工作组 (美国 Preventive Services Task Force) 等倡议的支持，从而提高了诊断率并扩大了患者覆盖范围。这一趋势与 ERLEAD® 的标靶机制相结合，与精准医疗的转型相契合，并为满足尚未满足的需求提供了机会。例如，2023 年核准的每日一次 240 毫克锭剂将提高患者的依从性并增强 ERLEAD® 的竞争地位。相关人员应专注于利用这些进步，在不断变化的治疗模式中保持市场领先地位。

目录

第一章调查方法与范围

第二章执行摘要

第三章 早期读者市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 早期阅读器市场：类型业务分析

  • 2024 年及 2033 年各类型市场占有率
  • 类型细分仪表板
  • 按类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 品牌
  • 非专利的

第五章 早期阅读器市场：通路业务分析

  • 2024年及2033年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医院药房
  • 零售药局
  • 其他的

第六章 早期领先市场：区域评估与趋势分析

  • 2024 年及 2033 年区域市场占有率分析
  • 区域市场仪表板
  • 2021-2033年市场规模与预测趋势分析
  • 北美洲
    • 按国家/地区，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Janssen Biotech, Inc.
    • Zydus Lifesciences
Product Code: GVR-4-68040-662-9

Erleada Market Summary

The global erleada market size was estimated at USD 2,999 million in 2024 and is projected to reach USD 6,166 million by 2033, growing at a CAGR of 7.99% from 2025 to 2033. The erleada industry is increasingly shaped by the push toward combination therapies to enhance treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC).

Phase 3 trials, such as NCT02257736, set to conclude in 2027, are evaluating Apalutamide alongside Abiraterone acetate and Prednisone to establish synergistic effects and potentially expand indications. By leveraging clinical data, like the SPARTAN trial's 70% reduction in metastasis risk (HR 0.28), stakeholders can strengthen payer negotiations and maintain market traction. The emphasis on combination therapies strengthens Erleada's position against emerging generics, like Zydus Lifesciences' Apalutamide Tablets, which received USFDA approval in March 2025, threatening Erleada's market exclusivity. Johnson & Johnson's patents, covering specific formulations until 2038, offer legal protection, but the potential for litigation remains a concern.

The market is influenced by the growing adoption of value-based care, particularly among U.S. payers like Medicare, who favor therapies with proven long-term benefits. Erleada's clinical evidence, including TITAN's 33% mortality risk reduction (HR 0.67), has driven real-world impact, with Medicare Advantage plans reporting a 10% reduction in nmCRPC patient hospitalizations in 2024 compared to alternatives. Stakeholders can enhance market resilience by generating real-world evidence to demonstrate cost-effectiveness and investing in healthcare provider education on Apalutamide's administration to boost adoption and mitigate the impact of generic competition.

The erleada industry benefits from keen awareness of early prostate cancer screening, supported by initiatives like those from the U.S. Preventive Services Task Force, which have increased diagnosis rates and expanded the eligible patient pool. This trend, coupled with Erleada's targeted mechanism, aligns with the shift toward precision medicine, offering opportunities to address unmet needs. For instance, the 2023 approval of a 240 mg once-daily tablet improved patient compliance, reinforcing Erleada's competitive positioning. Stakeholders should focus on leveraging these advancements to maintain market leadership amidst evolving treatment paradigms.

Global Erleada Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global erleada market report based on type, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded
  • Generic
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Erleada Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Erleada Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2021 - 2033 (USD Million)
  • 4.5. Generic
    • 4.5.1. Generic Market, 2021 - 2033 (USD Million)

Chapter 5. Erleada Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Erleada Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Erleada Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Janssen Biotech, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Zydus Lifesciences
      • 7.6.1.1. Overview
      • 7.6.1.2. Financial Performance
      • 7.6.1.3. Product Benchmarking
      • 7.6.1.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Erleada market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 5 Global Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 North America Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 8 North America Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 U.S. Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 Canada Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 12 Canada Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 Mexico Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 17 Europe Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18 UK Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 19 UK Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Germany Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 21 Germany Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 France Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 23 France Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Italy Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 25 Italy Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26 Spain Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 27 Spain Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Norway Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 29 Norway Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Denmark Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 31 Denmark Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Sweden Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 33 Sweden Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Japan Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 38 Japan Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 China Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 40 China Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 India Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 42 India Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Australia Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 44 Australia Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 South Korea Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 46 South Korea Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 Thailand Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 48 Thailand Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Latin America Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 51 Latin America Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Brazil Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 53 Brazil Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Argentina Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 55 Argentina Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 South Africa Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 60 South Africa Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63 UAE Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 64 UAE Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Kuwait Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait Erleada market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Erleada market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Erleada market dynamics
  • Fig. 12 Erleada market: Porter's five forces analysis
  • Fig. 13 Erleada market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Branded market, 2021 - 2033 (USD Million)
  • Fig. 16 Generic market, 2021 - 2033 (USD Million)
  • Fig. 17 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 18 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 19 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Erleada market revenue, by region
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 North America Erleada market, 2021 - 2033 (USD Million)
  • Fig. 24 US country dynamics
  • Fig. 25 US Erleada market, 2021 - 2033 (USD Million)
  • Fig. 26 Canada country dynamics
  • Fig. 27 Canada Erleada market, 2021 - 2033 (USD Million)
  • Fig. 28 Mexico country dynamics
  • Fig. 29 Mexico Erleada market, 2021 - 2033 (USD Million)
  • Fig. 30 Europe Erleada market, 2021 - 2033 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK Erleada market, 2021 - 2033 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany Erleada market, 2021 - 2033 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France Erleada market, 2021 - 2033 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy Erleada market, 2021 - 2033 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain Erleada market, 2021 - 2033 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway Erleada market, 2021 - 2033 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden Erleada market, 2021 - 2033 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark Erleada market, 2021 - 2033 (USD Million)
  • Fig. 47 Asia Pacific Erleada market, 2021 - 2033 (USD Million)
  • Fig. 48 Japan country dynamics
  • Fig. 49 Japan Erleada market, 2021 - 2033 (USD Million)
  • Fig. 50 China country dynamics
  • Fig. 51 China Erleada market, 2021 - 2033 (USD Million)
  • Fig. 52 India country dynamics
  • Fig. 53 India Erleada market, 2021 - 2033 (USD Million)
  • Fig. 54 Australia country dynamics
  • Fig. 55 Australia Erleada market, 2021 - 2033 (USD Million)
  • Fig. 56 South Korea country dynamics
  • Fig. 57 South Korea Erleada market, 2021 - 2033 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand Erleada market, 2021 - 2033 (USD Million)
  • Fig. 60 Latin America Erleada market, 2021 - 2033 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil Erleada market, 2021 - 2033 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina Erleada market, 2021 - 2033 (USD Million)
  • Fig. 65 MEA Erleada market, 2021 - 2033 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa Erleada market, 2021 - 2033 (USD Million)
  • Fig. 68 Saudi Arabia country dynamics
  • Fig. 69 Saudi Arabia Erleada market, 2021 - 2033 (USD Million)
  • Fig. 70 UAE country dynamics
  • Fig. 71 UAE Erleada market, 2021 - 2033 (USD Million)
  • Fig. 72 Kuwait country dynamics
  • Fig. 73 Kuwait Erleada market, 2021 - 2033 (USD Million)
  • Fig. 74 Company categorization
  • Fig. 75 Company market position analysis
  • Fig. 76 Strategic framework